Somatropin

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Small for Gestational Age (SGA)

Conditions

Small for Gestational Age (SGA)

Trial Timeline

Sep 5, 2013 → Jun 7, 2017

NCT ID

NCT01897766

About Somatropin

Somatropin is a pre-clinical stage product being developed by Pfizer for Small for Gestational Age (SGA). The current trial status is completed. This product is registered under clinical trial identifier NCT01897766. Target conditions include Small for Gestational Age (SGA).

What happened to similar drugs?

20 of 20 similar drugs in Small for Gestational Age (SGA) were approved

Approved (20) Terminated (2) Active (0)

✅mouse nerve growth factorSun PharmaceuticalApproved

✅Pemetrexed + CarboplatinEli LillyApproved

✅pemetrexedEli LillyApproved

✅Osimertinib+cisplatin or carboplatin + pemetrexed EditAstraZenecaApproved

✅DurvalumabAstraZenecaApproved

✅Gefitinib + DocetaxelAstraZenecaApproved

✅OsimertinibAstraZenecaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01897766	Pre-clinical	Completed	Sep 5, 2013	Jun 7, 2017	Small for Gestational Age (SGA)
NCT00793325	Pre-clinical	Completed	Feb 1, 2009	Dec 1, 2012	Small for Gestational Age
NCT00601419	Pre-clinical	Completed	Mar 1, 2007	Dec 1, 2012	Dwarfism, Growth Hormone Deficiency
NCT00174460	Phase 2	Completed	Aug 1, 2005	Mar 1, 2010	Growth Hormone Therapy
NCT00163189	Phase 3	Completed	Jan 1, 2005	Dec 1, 2014	Growth Hormone Deficiency
NCT00163215	Phase 3	Completed	Jan 1, 2005	Oct 1, 2011	Endocrine System Diseases
NCT00174291	Phase 3	Terminated	Mar 1, 2002	Oct 1, 2011	Endocrine System Diseases
NCT00174187	Phase 3	Terminated	Sep 1, 2000	Sep 1, 2011	Endocrine System Diseases
NCT00174278	Phase 3	Completed	Feb 1, 1997	Oct 1, 2006	Growth Hormone Deficiency

Competing Products

20 competing products in Small for Gestational Age (SGA)

See all competitors

Product	Company	Stage	Hype Score
mRNA-1769	Moderna	Phase 2	0
BBP-398 with nivolumab	BridgeBio Pharma	Phase 1	18
Pemetrexed + Carboplatin	Eli Lilly	Phase 3	40
Necitumumab + Gemcitabine + Carboplatin	Eli Lilly	Phase 2	27
Selpercatinib	Eli Lilly	Pre-clinical	26
Pemetrexed + Cisplatin + Placebo + Pemetrexed	Eli Lilly	Phase 3	40
NBTXR3	Nanobiotix	Phase 1/2	33
Pemetrexed	Eli Lilly	Pre-clinical	26
pemetrexed + erlotinib	Eli Lilly	Phase 2	35
LY3295668 Erbumine	Eli Lilly	Phase 1	29
FYB206 + FYB206 + Keytruda	Formycon AG	Phase 3	22
6-Thio-2'-Deoxyguanosine + Cemiplimab	MAIA Biotechnology	Phase 2	32
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine alone	MAIA Biotechnology	Phase 3	37
pemetrexed + cisplatin	Eli Lilly	Phase 2	27
gemcitabine + carboplatin + cisplatin	Eli Lilly	Phase 2	35
Cetuximab	Eli Lilly	Phase 1	29
pemetrexed + docetaxel	Eli Lilly	Phase 3	40
enzastaurin + pemetrexed + docetaxel + carboplatin	Eli Lilly	Phase 2	35
PemCarbo + Pem only	Eli Lilly	Phase 3	36
TNG456 + abemaciclib	Eli Lilly	Phase 1/2	39